LeonaBio Inc (LONA)

• Market cap: $84.5M
• 1 day: -5.46%
• 5 days: -0.55%
• 1 month: 6.51%
• 3 months: -5.06%
• 6 months: 41.96%
• Year to date: 29.31%
• 1 year: 127.27%
• 5 years: -90.93%
• 10 years: -94.74%
• Sector: Healthcare
• Industry: Biotechnology

About: LeonaBio Inc is a clinical-stage biopharmaceutical company focused on the development of novel therapeutics for high unmet medical needs. Its key drug candidates, lasofoxifene and ATH-1105, are novel, small-molecule therapies with the potential to address treatment-resistant metastatic breast cancer and amyotrophic lateral sclerosis (ALS). LeonaBio is also exploring the use of other drug candidates that enhance the neurotrophic HGF system, including ATH-1020, to improve neuronal health and function in multiple neurological diseases. In addition, it is also focused on designing and testing new early compounds directed towards novel targets for a variety of clinical applications. The company operates as a single operating segment, developing and commercializing therapeutics.

Employees: 19